fbpx

AstraZeneca Says its Coronavirus Vaccine Produces Immune Responses in Adults

AstraZeneca (OTCMKTS: AZNCF), a British Pharmaceutical, announced Monday that its trial COVID-19 vaccine has proved to produce an immune response within older and younger adults. The company’s shares rose 1% Monday during premarket trading.

 

According to the company, though the responses in older and younger adults were not identical, they were similar. Adverse responses to the vaccine, recognized as reactogenicity, were lower in senior individuals. 

The World Health organization communicated that older people along with those with preexisting medical conditions, often have severe consequences when exposed to the coronavirus. However AstraZeneca’s news insites hope of a possible reliable vaccine before the end of 2020.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesperson said. “The results further build the body of evidence for the safety and immunogenicity of [the vaccine].”

AstraZeneca is working on its potential COVID-19 vaccine in collaboration with Oxford University. Clinical trials are in the third phase alongside other developing vaccines from Pfizer and Moderna.

In September, the pharmaceutical company experienced difficulty after its vaccine trials were stopped amid a participant developing neurological symptoms. However The Food and Drug Administration gave it the green light to proceed on Friday. 

“The restart of clinical trials across the world is great news as it allows us to continue our efforts to develop this vaccine to help defeat this terrible pandemic,” AstraZeneca CEO Pascal Soriot said in a statement Friday. “We should be reassured by the care taken by independent regulators to protect the public and ensure the vaccine is safe before it is approved for use.”

Results for the vaccine will not be known until the data from the phase three trial is published.